Beyond ganglion cells: Novel foveal avascular zone features in MS with implications for vision loss

超越神经节细胞:多发性硬化症中新的中心凹无血管区特征对视力丧失的影响

基本信息

  • 批准号:
    10707139
  • 负责人:
  • 金额:
    $ 52.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-30 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Multiple sclerosis (MS) is a devastating neuro-degenerative disease that causes visual impairment in young, middle aged and older adults with resulting substantial lost productivity and cost to society. Current thinking attributes vision loss in MS to death and dysfunction of the retinal ganglion cells (RGCs) that comprise the optic nerve. However, there is only weak correlation between visual function and RGC atrophy, and some patients without RGC atrophy have vision loss, suggesting that all relevant contributors to vision loss in MS have not been identified. We have discovered structural features in the foveal avascular zone (FAZ) of retinas of the majority people with MS and a minority of people with glaucoma that cast a shadow on the photoreceptor layer and correlate with visual function. Our discovery contributes to addressing gaps in understanding visual pathway involvement in MS, offering new windows into diagnosis and treatment of vision loss in MS. This project studies the recently discovered FAZ features in retinas of people with MS and related diseases using adaptive optics scanning light ophthalmoscopy, a high resolution, non-invasive, state-of-the-art imaging technique. In the first aim, the relationship between central visual function and FAZ features will be defined using MS as an experimental model. Advanced microperimetry will be used to test the hypothesis that photoreceptor shadowing is the mechanism of vision loss. In the second aim the cause and composition of the FAZ features will be inferred through longitudinal studies of people with MS, cross sectional comparison between MS, glaucoma and related neurological and ophthalmic diseases and histopathological study of ex-vivo MS eyes. In the third aim rapid imaging protocols will be developed to enable faster detection of FAZ features and these will be applied to estimate the distributions of FAZ features in the populations with MS, glaucoma, other diseases and controls. These observations will evaluate the candidacy of the FAZ features as biomarkers of MS by defining specificity. The immediate impact of this research will be advancing understanding of vision loss in MS, developing rapid imaging strategies to enable broader study of large sample sizes at multiple sites and evaluating FAZ features as biomarkers in MS, glaucoma and other disease.
项目摘要 多发性硬化症(MS)是一种严重的神经退行性疾病,主要影响青、中年人的视力 以及老年人,从而导致生产力的大量损失和社会成本。目前认为视力丧失是由于 MS导致包括视神经的视网膜神经节细胞(RGC)的死亡和功能障碍。然而,只有 视功能与RGC萎缩的相关性较弱,部分无RGC萎缩的患者视力下降, 这表明尚未确定MS中视力丧失的所有相关因素。我们发现了结构性的 大多数MS患者和少数MS患者的视网膜中央凹无血管区(FAZ)的特征 在感光层上投射阴影并与视觉功能相关的青光眼。我们的发现有助于 解决在理解MS视觉通路参与方面的差距,为诊断和治疗提供新的窗口 该项目研究了最近发现的FAZ功能在视网膜的人与MS和相关 疾病使用自适应光学扫描光检眼镜,高分辨率,非侵入性,国家的最先进的成像 法在第一个目标中,将使用MS定义中央视觉功能和FAZ特征之间的关系, 实验模型。先进的微视野将被用来测试假设感光阴影是 视力丧失的机制。在第二个目标的原因和组成的FAZ功能将推断通过 MS患者的纵向研究,MS、青光眼和相关神经系统疾病之间的横断面比较, 眼科疾病和离体MS眼睛的组织病理学研究。在第三个目标中,快速成像协议将是 开发了一种快速检测FAZ特征的方法,这些方法将用于估计FAZ特征的分布 在患有多发性硬化症、青光眼、其他疾病和对照的人群中。这些意见将评估候选人的资格。 FAZ通过定义特异性作为MS的生物标志物。这项研究的直接影响将是 了解MS中的视力丧失,开发快速成像策略,以实现更广泛的大样本量研究, 多个站点和评估FAZ功能作为MS,青光眼和其他疾病的生物标志物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heather Elspeth Moss其他文献

Heather Elspeth Moss的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heather Elspeth Moss', 18)}}的其他基金

Beyond ganglion cells: Novel foveal avascular zone features in MS with implications for vision loss
超越神经节细胞:多发性硬化症中新的中心凹无血管区特征对视力丧失的影响
  • 批准号:
    10756395
  • 财政年份:
    2023
  • 资助金额:
    $ 52.07万
  • 项目类别:
Beyond ganglion cells: Novel foveal avascular zone features in MS with implications for vision loss
超越神经节细胞:多发性硬化症中新的中心凹无血管区特征对视力丧失的影响
  • 批准号:
    10522605
  • 财政年份:
    2022
  • 资助金额:
    $ 52.07万
  • 项目类别:
Retinal vessel features as a marker of idiopathic intracranial hypertension treatment response: a secondary analysis of the idiopathic intracranial hypertension treatment trial
视网膜血管特征作为特发性颅内高压治疗反应的标志:特发性颅内高压治疗试验的二次分析
  • 批准号:
    10223317
  • 财政年份:
    2020
  • 资助金额:
    $ 52.07万
  • 项目类别:
Retinal vessel features as a marker of idiopathic intracranial hypertension treatment response: a secondary analysis of the idiopathic intracranial hypertension treatment trial
视网膜血管特征作为特发性颅内高压治疗反应的标志:特发性颅内高压治疗试验的二次分析
  • 批准号:
    10043677
  • 财政年份:
    2020
  • 资助金额:
    $ 52.07万
  • 项目类别:
Physiologically Based Markers of Idiopathic Intracranial Hypertension
特发性颅内高压的生理标志物
  • 批准号:
    9343081
  • 财政年份:
    2016
  • 资助金额:
    $ 52.07万
  • 项目类别:
Physiologically Based Markers of Idiopathic Intracranial Hypertension
特发性颅内高压的生理标志物
  • 批准号:
    9457463
  • 财政年份:
    2016
  • 资助金额:
    $ 52.07万
  • 项目类别:
Physiologically Based Markers of Idiopathic Intracranial Hypertension
特发性颅内高压的生理标志物
  • 批准号:
    9262224
  • 财政年份:
    2016
  • 资助金额:
    $ 52.07万
  • 项目类别:
Physiologically Based Markers of Idiopathic Intracranial Hypertension
特发性颅内高压的生理标志物
  • 批准号:
    8679930
  • 财政年份:
    2014
  • 资助金额:
    $ 52.07万
  • 项目类别:
Physiologically Based Markers of Idiopathic Intracranial Hypertension
特发性颅内高压的生理标志物
  • 批准号:
    8827356
  • 财政年份:
    2014
  • 资助金额:
    $ 52.07万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.07万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了